Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone

Trial Profile

Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Antisense K-ras RNA gene therapy (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PROTACT
  • Sponsors Silenseed
  • Most Recent Events

    • 14 Nov 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2019.
    • 14 Nov 2017 Planned initiation date changed from 1 Feb 2017 to 1 Nov 2017.
    • 18 Oct 2016 Planned number of patients changed from 124 to 80.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top